Education regarding gene therapies/one-time treatments; policies and regulations impacting drugs for rare diseases and conditions; FDA modernization
2025 · 1st Quarter (Jan 1 - Mar 31)
SPARK THERAPEUTICS, INC.
Filed by JEFFREY J. KIMBELL & ASSOCIATES, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- JEFFREY J. KIMBELL & ASSOCIATES, INC.
- Client
- SPARK THERAPEUTICS, INC.
- Filing UUID
- d9f915b7-f673-4015-8f04-5748c7d613fb
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Value-based pricing arrangements; MVP Act - HR 2666
Literal federal measure citations: HR 2666
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.